[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prokidney Corp (PROK)

Prokidney Corp (PROK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

ProKidney's Loss Narrative Continues, But the Timing of Profitability Remains Anyone's Guess

ProKidney Corp reports first-quarter 2026 earnings on May 18, 2026, with analysts expecting the clinical-stage biotech to post a loss of $0.13 per share. The central question for investors is whether the company can maintain its recent track record of beating estimates while advancing its regenerative cell therapy platform for chronic kidney disease. With the stock trading at $1.66 and down sharply from its 52-week high, this report will test whether ProKidney's clinical progress can offset mounting losses and deteriorating technical momentum.

ProKidney Corp is a clinical-stage biotechnology company developing REACT, an autologous cellular regenerative therapy designed to treat chronic kidney disease by stabilizing or...

Fundamentals

See More
  • Market Capitalization, $K 501,181
  • Shares Outstanding, K 301,916
  • Annual Sales, $ 890 K
  • Annual Income, $ -68,990 K
  • EBIT $ -165 M
  • EBITDA $ -158 M
  • 60-Month Beta 1.70
  • Price/Sales 578.14
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 196.76% (-11.36%)
  • Historical Volatility 54.81%
  • IV Percentile 48%
  • IV Rank 12.36%
  • IV High 966.89% on 01/09/26
  • IV Low 88.15% on 01/07/26
  • Expected Move (DTE 33) 0.1700 (10.24%)
  • Put/Call Vol Ratio 2.57
  • Today's Volume 75
  • Volume Avg (30-Day) 133
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 8,924
  • Open Int (30-Day) 7,976
  • Expected Range 1.4900 to 1.8300

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 3
  • High Estimate $-0.12
  • Low Estimate $-0.13
  • Prior Year $-0.13
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5900 +4.40%
on 05/15/26
2.1900 -24.20%
on 04/17/26
-0.3500 (-17.41%)
since 04/15/26
3-Month
1.5600 +6.41%
on 03/30/26
2.6050 -36.28%
on 03/10/26
-0.3200 (-16.16%)
since 02/13/26
52-Week
0.5400 +207.41%
on 06/30/25
7.1300 -76.72%
on 07/09/25
+0.8103 (+95.36%)
since 05/15/25

Most Recent Stories

More News
ProKidney's Loss Narrative Continues, But the Timing of Profitability Remains Anyone's Guess

Barchart Research What to Expect from PROK Earnings PROK Generated May 15, 2026 Current Price $1.6600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Loss Narrative Continues,...

PROK : 1.6600 (-2.92%)
ProKidney's Loss Narrative Continues, But the Timing of Profitability Remains Anyone's Guess

Barchart Research What to Expect from PROK Earnings PROK Generated May 15, 2026 Current Price $1.6600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Loss Narrative Continues,...

PROK : 1.6600 (-2.92%)
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 Peer-reviewed results from the Phase...

PROK : 1.6600 (-2.92%)
ProKidney's Earnings Call Will Test Whether Biotech Investors Still Believe in Kidney Regeneration

Barchart Research What to Expect from PROK Earnings PROK Generated May 8, 2026 Current Price $1.8600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Earnings Call Will...

PROK : 1.6600 (-2.92%)
ProKidney's Earnings Call Will Test Whether Biotech Investors Still Believe in Kidney Regeneration

Barchart Research What to Expect from PROK Earnings PROK Generated May 8, 2026 Current Price $1.8600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Earnings Call Will...

PROK : 1.6600 (-2.92%)
ProKidney's Earnings Call Will Test Whether Biotech Investors Still Believe in Kidney Regeneration

Barchart Research What to Expect from PROK Earnings PROK Generated May 8, 2026 Current Price $1.8600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Earnings Call Will...

PROK : 1.6600 (-2.92%)
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney...

PROK : 1.6600 (-2.92%)
ProKidney Reports Full Year 2025 Financial Results and Business Highlights

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned...

PROK : 1.6600 (-2.92%)
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)  (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney...

PROK : 1.6600 (-2.92%)
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025 More than half of...

PROK : 1.6600 (-2.92%)

Business Summary

ProKidney LP is a late clinical-stage cellular therapeutics company focused on CKD. The company's lead product candidate includes REACT(TM) is a first-of-its-kind, patented disease-modifying autologous cellular therapy. ProKidney LP, formerly known as Suvretta Holdings Corp. III, is based in WINSTON-SALEM,...

See More

Key Turning Points

3rd Resistance Point 1.8700
2nd Resistance Point 1.8000
1st Resistance Point 1.7300
Last Price 1.6600
1st Support Level 1.5900
2nd Support Level 1.5200
3rd Support Level 1.4500

See More

52-Week High 7.1300
Fibonacci 61.8% 4.6126
Fibonacci 50% 3.8350
Fibonacci 38.2% 3.0574
Last Price 1.6600
52-Week Low 0.5400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.